Health Care Equipment

GlucoTrack

GlucoTrack released FY2026 Q1 earnings on May 14 (EST), actual revenue USD 0, actual EPS USD -2.6499

GlucoTrack released FY2025 Q4 earnings on March 30 (EST), actual revenue USD 0, actual EPS USD -3.977

GlucoTrack released FY2025 Annual Earnings on March 30 (EST), with actual revenue of USD 0 and EPS of USD -31.2158

GlucoTrack released FY2025 9 Months earnings on November 13 (EST), actual revenue USD 0, actual EPS USD -54.6045

GlucoTrack released FY2025 Q3 earnings on November 13 (EST), actual revenue USD 0, actual EPS USD -4.6374

GlucoTrack released FY2025 Semi-Annual earnings on August 14 (EST), actual revenue USD 0, actual EPS USD -34.809

GlucoTrack released FY2025 Q2 earnings on August 14 (EST), actual revenue USD 0, actual EPS USD -9.6177

GlucoTrack Inc. Repurchased Warrants to Strengthen Capital Structure

GlucoTrack Inc. Reports Positive First-in-Human Study Results for Continuous Blood Glucose Monitor

Glucotrack to Showcase Advanced Continuous Glucose Monitoring Technology

Glucotrack Inc. to Hold a Webinar on Its CBGM Technology

GlucoTrack released FY2025 Q1 earnings on May 14 (EST) with actual revenue of USD 0 and EPS of USD -40.3493

GlucoTrack Expects FDA Approval in Q4 2025

GlucoTrack Inc. Secures Ethical Approval for Long-term CGM Clinical Trial

GlucoTrack released FY2024 Q4 earnings on March 31, 2025 (EST) with actual revenue USD 0 and EPS USD 0

GlucoTrack released FY2024 Annual Earnings on March 31 (EST) with actual revenue of USD 0 and EPS of USD 0

GlucoTrack Prices 2.6 Million Shares at $1.15 Each to Raise Approximately $3 Million

Glucotrack, Inc. Completes First Human Clinical Study, Continuous Blood Glucose Monitoring Device Successfully Achieves Primary Endpoint

Glucotrack Obtains ISO 13485:2016 Certification, Marking a Significant Milestone in Quality Commitment for Continuous Blood Glucose Monitoring Devices

GlucoTrack released FY2024 9 Months Earnings on November 14, 2024 (EST) with actual revenue of USD 0 and EPS of USD 0

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

GIPR

GCTK

Generation Income Properties pre-market down 17.13%; GlucoTrack pre-market down 13.67%; GCL Global pre-market up 124.00%; Tian Di Hui Food pre-market up 87.69%; WORK Medical Tech pre-market up 74.72%

Price Alert

Generation Income Properties

WORK Medical Tech

Pre-market hot trades in US stocks: Generation Income Properties down 17.13% pre-market; GlucoTrack down 13.67% pre-market

CAST

GlucoTrack pre-market up 11.80%; Freecast pre-market down 11.35%; Amesite pre-market up 197.51%; Rubico pre-market up 141.05%; Meiwukeji pre-market up 71.80%

Freecast

Amesite

Rubico

Meiwu Tech

Pre-market hot trades in US stocks: GlucoTrack up 11.80% in pre-market; Freecast down 11.35% in pre-market

GlucoTrack (GCTK) faces delisting risk after receiving multiple deficiency notices from Nasdaq. The first notice, dated May 11, 2026, indicated non-compliance with the $1.00 minimum bid price requirement. A second notice on May 15 cited insufficient stockholders' equity below $2.5 million. The company plans to request a hearing by May 18 to address these issues. Spark's AI Analyst rates GCTK as Neutral due to weak financial performance and bearish technicals, despite some positive corporate milestones.

Tip Ranks

GlucoTrack Faces Multiple Nasdaq Deficiency Notices, Delisting Risk

Earnings Watch

GlucoTrack | 10-Q: FY2026 Q1 Revenue: USD 0

GlucoTrack | 8-K: FY2026 Q1 Revenue: USD 0

SBIO

LABU

Glucotrack, Inc. (Nasdaq: GCTK) reported its Q1 2026 financial results, highlighting significant advancements in its continuous blood glucose monitoring (CBGM) technology. The company submitted an Investigational Device Exemption (IDE) application to the FDA for a U.S. clinical study, targeting a launch in the second half of 2026. Financially, Glucotrack reduced its net loss to $4.3 million from $6.8 million year-over-year, while cash and cash equivalents decreased to $3.9 million. The company also published peer-reviewed studies supporting its technology's efficacy and stability.

StockTitan

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

iShares US Medical Devices

iShares Biotechnology ETF

VanEck Biotech ETF

Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | GCTK Stock News

AVTX

APUS

TMDX

PAVM

AKAN

MNKD

In Wednesday's pre-market session, Avalo Therapeutics (AVTX) saw a significant gain of 50.9%, reaching $24.53, while GlucoTrack (GCTK) rose by 45.2% to $1.06. Other notable gainers included Simulations Plus (SLP) up 35.66% and MannKind (MNKD) up 20.27%. Conversely, PAVmed (PAVM) dropped 27.9% to $5.8, and Apimeds Pharmaceuticals (APUS) fell 27.67% to $2.17. TransMedics Group (TMDX) and Akanda (AKAN) also experienced declines of 22.04% and 19.22%, respectively. The fluctuations follow recent earnings reports for Q1 and Q4.

benzinga_article

Avalo Therapeutics

Apimeds Pharmaceuticals US

TransMedics

PAVmed

Akanda

Simulations Plus

Mannkind

Cypherpunk Tech

Atlantic

Hyperion DeFi

Alphatec

ATLANTIC INTERNATIONAL CORP C/WTS 31/08/2026 (TO PUR COM)

PAVMED INC C/WTS 30/04/2025(TO PUR COM) CLASS Z

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

GlucoTrack（GCTK.US）现价 $0.8744，当日 +4.47%，盘中短线涨幅一度超过 10%，市值 0.02 亿。该公司聚焦血糖检测设备，今日受医疗板块整体情绪带动，股价多次快速波动。近期无重大公告，异动或与短线资金情绪有关。

Movers Alert

SPDR S&P Health Equip

GlucoTrack Shares Surge Amid Healthcare Momentum

GlucoTrack（GCTK.US）现价 $1.08，当日 +29.03%，盘中涨幅显著扩大，市值约 450 万美元。公司定位于无创血糖检测设备，股价于盘中出现剧烈上涨，近期医疗健康领域资金流入明显。暂无重大公告，异动或因短线资金追逐和板块活跃行情。

GlucoTrack soars over 29% on sector momentum

GlucoTrack(GCTK.US)